https://www.selleckchem.com/pr....oducts/tucidinostat-
No differences in IBTR or BCSD risk were detected. RT benefit regarding IBTR risk was significant in the PDGFRb low (0.29, 0.12-0.67, p = 0.004) and medium (0.31, 0.16-0.59, p 0.001) groups but not the PDGFRb high group (0.64, 0.36-1.11, p = 0.11 in multivariable analysis. Likewise, risk reduction for any recurrence was less pronounced in the PDGFRb high group. No significant interaction between RT and PDGFRb-score could be detected. A higher PDGFRb-score conferred an increased risk of any recurrence, which partly
Мне нравится
Комментарий
Перепост
